Tacrolimus Trough Level Variation and Its Correlation to Clinical Outcomes and Consequences in Solid Organ Transplantation

References

• Kaczmarek I, Zaruba -M-M, Beiras-Fernandez A, et al. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. J Heart Lung Transplant. 2013;32:277–284. doi:10.1016/j.healun.2012.11.028
   PubMed Web of Science ®Google Scholar
• Neurohr C, Huppmann P, Zimmermann G, et al. Tacrolimus and mycophenolate mofetil as first-line immunosuppression after lung transplantation. Transpl Int. 2009;22:635–643. doi:10.1111/j.1432-2277.2009.00843.x
   PubMed Web of Science ®Google Scholar
• Griffith BP, Bando K, Hardesty RL, Armitage JM. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation. 1994;57:848–851. doi:10.1097/00007890-199403270-00013
   PubMed Web of Science ®Google Scholar
• Treede H, Glanville AR, Klepetko W, et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant. 2012;31:797–804. doi:10.1016/j.healun.2012.03.008
   PubMed Web of Science ®Google Scholar
• Guethoff S, Meiser BM, Groetzner J, et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine in combination with mycophenolate mofetil after heart transplantation. Transplantation. 2013;95:629–634. doi:10.1097/TP.0b013e318277e378
   PubMed Web of Science ®Google Scholar
• Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant. 2002;2:989–992. doi:10.1034/j.1600-6143.2002.21018.x
   PubMed Web of Science ®Google Scholar
• Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5mg single oral doses to healthy human subjects. J Clin Pharmacol. 2001;41:176–182. doi:10.1177/00912700122009999
   PubMed Web of Science ®Google Scholar
• Monchaud C, de Winter BC, Knoop C, et al. Population pharmacokinetic modeling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 2012;51:175–186. doi:10.2165/11594760-000000000-00000
   PubMed Web of Science ®Google Scholar
• Phapale PB, Kim S-D, Lee HW, et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin Pharmacol Ther. 2010;87:426–436. doi:10.1038/clpt.2009.296
   PubMed Web of Science ®Google Scholar
• Undre NA, Meiser BM, Uberfuhr P, et al. Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. Transplant Proc. 1998;30:1112–1115. doi:10.1016/S0041-1345(98)00173-0
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Piekoszewski W, Klintmalm GB. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57:281–290. doi:10.1016/0009-9236(95)90153-1
   PubMed Web of Science ®Google Scholar
• Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46:27–35. doi:10.1016/S1056-8719(02)00158-2
   PubMed Web of Science ®Google Scholar
• Wallemacq DPE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in pediatric and adult patients. Clin Pharmacokinet. 2001;40:283–295. doi:10.2165/00003088-200140040-00004
   PubMed Web of Science ®Google Scholar
• Chow F-S, Piekoszewski W, Jusko WJ. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos. 1997;25:610–616.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623–653. doi:10.2165/00003088-200443100-00001
   PubMed Web of Science ®Google Scholar
• Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016;12:555–565. doi:10.1517/17425255.2016.1170808
   PubMed Web of Science ®Google Scholar
• Oetting WS, Schladt DP, Guan W, et al. Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identify multiple CYP3A5 alleles. Am J Transplant. 2016;16:574–582. doi:10.1111/ajt.13495
   PubMed Web of Science ®Google Scholar
• van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25:707–712. doi:10.2165/00002018-200225100-00003
   PubMed Web of Science ®Google Scholar
• Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64(6):750–757. doi:10.1111/j.1365-2125.2007.02895.x
   PubMed Web of Science ®Google Scholar
• de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009;31(4):416–435. doi:10.1097/FTD.0b013e3181aa36cd
   PubMed Web of Science ®Google Scholar
• Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67(6):2440–2447. doi:10.1111/j.1523-1755.2005.00352.x
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141–175. doi:10.2165/11317350-000000000-00000
   PubMed Web of Science ®Google Scholar
• Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev. 2015;29(2):78–84. doi:10.1016/j.trre.2015.01.002
   Web of Science ®Google Scholar
• Andrews LM, de Winter BC, Tang JT, et al. Overweight kidney transplant recipients are at risk of being overdosed following standard body weight-based tacrolimus starting dose. Transplant Direct. 2017;3:e129. doi:10.1097/TXD.0000000000000644
   PubMed Web of Science ®Google Scholar
• Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721–726. doi:10.1038/clpt.2010.17
   PubMed Web of Science ®Google Scholar
• Waiser J, Slowinski T, Brinker-Paschke A, et al. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant. 2002;17(7):1310–1317. doi:10.1093/ndt/17.7.1310
   PubMed Web of Science ®Google Scholar
• Whalen HR, Glen JA, Harkins V, et al. High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime. Transplantation. 2017;101(2):430–436. doi:10.1097/TP.0000000000001129
   PubMed Web of Science ®Google Scholar
• Hsiau M, Fernandez HE, Gjertson D, Ettenger RB, Tsai EW. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. Transplantation. 2011;92(8):918–922. doi:10.1097/TP.0b013e31822dc34f
   PubMed Web of Science ®Google Scholar
• Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85(6):1404–1411. doi:10.1038/ki.2013.465
   PubMed Web of Science ®Google Scholar
• Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25(8):2757–2763. doi:10.1093/ndt/gfq096
   PubMed Web of Science ®Google Scholar
• Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective. Pharmacotherapy. 2021;41(1):103–118. doi:10.1002/phar.2480
   PubMed Web of Science ®Google Scholar
• Alghanem Sarah S, Soliman Moetaza M, Alibrahim Ali A, Osama G, Kenawy Ahmed S, Abdelmoneim A. Monitoring tacrolimus trough concentrations during the first year after kidney transplantation: a national retrospective cohort study. Front Pharmacol. 2020;2020:11.
   Google Scholar
• Huang CT, Shu KH, Ho HC, Wu MJ. Higher variability of tacrolimus trough level increases risk of acute rejection in kidney transplant recipients. Transplant Proc. 2016;48:1978–1980. doi:10.1016/j.transproceed.2016.02.081
   PubMedGoogle Scholar
• Giza P, Ficek R, Dwulit T, et al. Number of regularly prescribed drugs and intrapatient tacrolimus trough levels variability in stable kidney transplant recipients. J Clin Med. 2020;9(6):1926. doi:10.3390/jcm9061926
   PubMed Web of Science ®Google Scholar